Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc

Maria-Paz Garcia-Cuellar, Andreas Prinz and Robert K. Slany
Department of Genetics, Friedrich-Alexander-University Erlangen-Nürnberg, Germany

Abstract

The homeobox transcription factors HoxA9 and Meis1 are causally involved in the etiology of acute myeloid leukemia. While HoxA9 alone immortalizes cells, cooperation with Meis1 is necessary to induce a full leukemic phenotype. Here, we applied degron techniques to elucidate the leukemogenic contribution of Meis1. Chromatin immunoprecipitation experiments revealed that Meis1 localized mainly to H3K27 acetylated and H3K4 mono-methylated enhancers pre-activated by HoxA9. Chromatin association of Meis1 required physical presence of HoxA9 and all Meis1 DNA interactions were rapidly lost after HoxA9 degradation. Meis1 controlled a gene expression pattern dominated by Myc, ribosome biogenesis and ribosomal RNA synthesis genes. While Myc accounted for the cell cycle stimulating effect of Meis1, overexpression of this oncogene alone did not accelerate leukemogenesis. Besides its effect on Myc, Meis1 induced transcription of ribosomal biogenesis genes. This was accompanied by an elevated resistance against inhibition of ribosomal RNA synthesis and translation, but without affecting steady-state protein synthesis. Finally, we demonstrate that HoxA9 and Meis1 proteins are stabilized by post-translational modification. Mutation of HoxA9/Meis1 phosphorylation sites or inhibition of casein kinase 2 lead to rapid protein degradation suggesting a potential pathway for pharmacological intervention.

Introduction

Besides their function during embryogenesis, Hox-homeobox transcription factors are well established oncoproteins in acute leukemia. Particularly, HOXA9 is frequently over-expressed in hematopoietic malignancies and HOXA9 expression is an independent negative prognostic factor.\(^1\),\(^2\) Reflecting the tendency of homeobox proteins to form heteromultimers, overexpression of HOXA9 in leukemia is almost always accompanied by equally elevated levels of MEIS1 and PBX3, two members of the “three amino acid loop extension” (TALE) homeobox family. Biochemical evidence showed that the PBX/MEIS interaction is required for nuclear import of the dimers.\(^3\) In addition, Pbx3 protects Meis1 from proteosomal degradation.\(^4\) As a consequence of this molecular cooperation experimental introduction of HoxA9 immortalizes hematopoietic precursor cells, but HoxA9 alone does not induce aggressive disease. Full leukemogenesis requires addition of Meis1 and can be exacerbated further by increasing Pbx3.\(^4\),\(^5\) While known for a long time a detailed molecular explanation for this enhancer effect is still missing. Previous attempts to clarify this phenomenon concentrated on a steady-state comparison of HoxA9 versus HoxA9/Meis1-expressing cells. This approach makes it hard to distinguish primary effects of Meis1 from subordinate events. Nevertheless, the gene for the receptor tyrosine kinase Flt3 could be identified as a target gene of Meis1.\(^6\) Abnormally active FLT3 signaling is clearly involved in the etiology of acute myeloid leukemia as demonstrated by the presence of activating FLT3 mutations in patients.\(^7\) Yet, Flt3 overexpression could be ruled out as a reason for the Meis1-dependent leukemic enhancer effect. A complete genetic ablation of Flt3 in animals did neither alter the incidence nor the kinetics of leukemia experimentally induced by HoxA9/Meis1 or by MLL fusions that induce strong transcription of HoxA9/Meis1 as target genes.\(^8\)\(^9\) Hence, while Flt3 is a suitable sentinel gene for Meis1 activity, other mechanisms must be responsible for the phenotypic outcome. A recent study\(^10\) found increased Syk signaling in...
HoxA9/Meis1-transformed myeloid cells. Increased Syk activity indirectly recapitulated part of the Meis1 phenotype. Mechanistically, Syk activity was controlled by a PU.1/miRNA loop that was more active in Meis1-containing cells, however Meis1 did not control Syk transcription.

Meis1 has also been shown to affect hypoxia signaling in hematopoietic and leukemic stem cells by controlling HIF1α expression, a feature important for survival and proper development of these cells. Yet, in essence, a comprehensive study identifying direct and immediate Meis1 target genes is still missing, mainly, because suitable conditional Meis1 expression systems were not available. Strikingly, hematopoietic development is especially sensitive towards perturbation of ribosomal biogenesis. This is best exemplified by the well characterized congenital anemias caused by inherited mutations in ribosomal proteins and also in ribosome biogenesis factors like Diamond-Blackfan-Anemia, Dyskeratosis Congenita, and Shwachman-Diamond Syndrome (for a review Sulima et al.). While initially characterized by a paucity of blood cells (anemia) many patients later go on to develop acute leukemia. This is elicited by secondary mutations occurring in hematopoietic precursors that are under continuous proliferative stress to supply the necessary number of blood cells. The conspicuous involvement of ribosomal proteins and ribosome biogenesis factors, including small nucleolar RNA, in these syndromes has led to the general designation of “ribosomopathy” to summarize these pathologies. The list of genes involved in this disease etiology is growing with DDX41, a protein necessary for ribosome production, as the genes involved in this disease etiology is growing with DDX41, a protein necessary for ribosome production, as the genes involved in this disease etiology is growing with DDX41, a protein necessary for ribosome production, as the most recent addition. It should be noted that there is no evidence that hematopoietic cells would contain more ribosomes or display a generally higher protein synthesis activity than other cells. Rather, the rapid supply of sufficient ribosomes in a short time frame is essential for rapid cell division that sustains the extraordinary proliferative activity of hematopoietic precursors. Here we demonstrate that Meis1 boosts HoxA9 activity through two major mechanisms. First, Meis1 amplifies a Myc program that is known to be pre-initiated by HoxA9 and second, Meis1 enhances ribosomal production as prerequisites for efficient leukemogenesis.

Methods

A detailed description of the methods applied can be found in the Online Supplementary Appendix.

Cells

Transformed primary cells were maintained in RPMI1640 supplemented with 10% fetal calf serum, penicillin-streptomycin, 5 ng/mL recombinant murine interleukin 3 (IL-3), IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF), and 50 ng/mL recombinant murine stem cell factor (SCF). Hematopoietic stem and precursor cells (HSPC) were isolated either from wild-type (wt) or C57/BL6 mice with a triple knockout (ko) for Elane, Prtn3, and Ctsg.

Chromatin immunoprecipitation sequencing, cell lysis, nascent RNA isolation, sequencing

Chromatin immunoprecipitation (ChIP) was performed as previously described in . Nascent RNA isolation was done exactly as described in . Next generation sequencing (NGS) libraries were generated with NEBNext Ultra II DNA Library Prep Kit reagents and NEBNext Single Cell/Low Input RNA Library Prep kits, respectively. Sequencing was done in house with an Illumina standard pipeline.

Bioinformatics

Data were mapped with BWA mem (0.7.17) to the Mus musculus mm10 genome. For visualization the IGV browser package was used. Peak finding, motif analysis and peak annotation was done with Homer (4.9.1). BAM files were converted to bigwig and plots were created by Deeptools (3.0.0, bamCoverage). RNA derived reads were aligned to the reference genome mm10 with STAR (v020201) and reads derived from repetitive sequences were excluded by samtools (view).18

Transplantation experiments

Transplants were syngenic with donor cells and recipients of C57/BL6 background. Animals were sublethally irradiated (6 Gy) before receiving 0.5x106 transduced cells and 0.5x105 total bone marrow cells for radiation protection. All procedures were approved by the Institutional and State Review Boards (IRB) and license numbers are available on request.

Data availability

Raw NGS reads were submitted to the European Nucleotide Archive under accession number ERP134562/PRJEB50012.

Statistics

Where appropriate two-tailed t-test statistics were applied.

Results

Meis is an enhancer binding factor

In order to determine genome-wide binding patterns by ChIP we generated myeloid precursor cell lines by retrovirally transducing primary HSPC with a combination of HoxA9, Meis1, and Pbx3, where one of the three proteins was individually HA-epitope tagged for each experiment (Figure 1A). In addition, HSPC were also transduced with a combination of HoxA9 and a HA-tagged Meis1 fused to a mutated (F36V) FKBP. FKBP36V is a “degron” sequence
allowing controlled elimination of the fusion protein by adding the PROTAC (proteolysis targeting chimera) dTAG13 that bridges FKBP_{36}^V and the endogenous E3 ubiquitin ligase cereblon, thus allowing rapid proteasomal degradation of the targeted protein.\(^{31}\)

For ChIP HSPC were derived from animals with a complete ko of the myeloid granule proteases elastase, proteinase 3 and cathepsin G (EPC mice).\(^{22}\) This was necessary because preliminary experiments (Online Supplementary Figure S1A) showed that Meis1 is subject to rapid degradation by these proteases if they are released by cell lysis similar to what we have described previously for HoxA9.\(^{21}\) This proteolysis can only be stopped by rapid SDS-based denaturation of proteins but it is not inhibited by commercial protease inhibitors. Because cell disruption is required for ChIP, this method liberates granule proteases and efficient precipitation of Meis1-bound chromatin requires a protease negative environment (Online Supplementary Figure S1B).

Expression of individual proteins in the resulting precursor cell lines as well as functional degradation of Meis1-FKBPF_{36}^V after addition of dTAG13 was checked by western blot (Figure 1B) indicating that 8 hours (h) after addition of dTAG13 no Meis1-FKBPF_{36}^V was detectable any more. ChIP for Meis1 was performed with an anti-HA antibody in a duplicate utilizing “constitutive” cell lines, and additionally, with cells containing degradable Meis1-FKBPF_{36}^V before and 8 h after dTAG13 was added. NGS of ChIP precipitates revealed highly efficient enrichment of Meis1 bound chromatin with low

---

**Figure 1. Meis1 binds preferentially to enhancers.** (This figure is supplemented by the Online Supplementary Figure S1). (A) Strategy to generate primary transformed cell lines for chromatin immunoprecipitation (ChIP) experiments: hematopoietic stem and precursor cells (HSPC) were isolated from animals with a genetic knockout of myeloid granule proteases elastase, proteinase 3, and cathepsin G to allow for efficient ChIP. (B) Expression of ChIP targets and induced degradation of Meis1-FKBPF_{36}^V. Extracts from transformed primary cells were probed by HA-specific western for constitutive expression (left panel) of ChIP targets and for induced degradation of Meis1-FKBPF_{36}^V after addition of dTAG13 (a “proteolysis targeting chimera”; PROTAC) (right panel). (C) Meis1 ChIP is reproducible and peaks can be verified by Meis1 degradation. Integrated genomics viewer (IGV) panels showing Meis1 binding patterns at 2 typical Meis1 loci, Myb and its major enhancer (top panel) and the known Meis1-responsive gene Flt3 (lower panel). Tracks correspond to a replicate obtained with constitutively expressed Meis1 as well as Meis1-FKBPF_{36}^V before and 8 hours after initiation of degradation as labeled. An input track is added as control. (D) Meis1 localizes predominantly to putative enhancer locations. Pie chart of Meis1 peak distribution across functionally annotated genetic elements. Analysis was done for the 10,000 top scoring peaks.
background and good congruency between individual samples (Figure 1C). A preliminary pass of a peak-finding algorithm resulted in more than 24,000 identifiable binding sites. For further analysis we decided to concentrate on the top-scoring 10,000 peaks with highest read density, because these encompassed those with the best correlation between replicates (spearman correlation 0.84 between replicates and 0.74 between Meis1 and Meis1-FKBP\textsuperscript{36V}, Online Supplementary Figure S1C). Reassuringly, correlation broke down (Spearman correlation 0.16) after addition of dTAG13, indicating that these peaks correspond to high-confidence Meis1 binding sites.

Functional annotation revealed that nearly 90% of peaks (8,838/10,000) localized to introns or intergenic regions with only 791 binding sites (~8%) annotated as “promoter” (Figure 1D). As this strongly suggested a mainly enhancer-centered distribution, we determined enhancer-typical chromatin modifications H3K27ac and H3K4me1 in the same cell lines (Figure 2A and B). As expected, these enhancer marks were highly enriched around Meis1 binding sites with Meis1 localizing to typical modification “valleys”. Generally, higher scoring Meis1 peaks corresponded also to higher H3K27ac modification levels whereas the activation independent enhancer mark H3K4me1 was present around Meis1 sites but did not correlate to Meis1 binding strength. A de novo motif search of Meis1 bound sequences revealed

**Figure 2. Meis1 binding sites colocalize with enhancer-typical chromatin modifications.** (A) Meis1 co-localizes with enhancer-typical chromatin modifications H3K27ac (active enhancer) and H3K4me1 (putative enhancer) around the top 10,000 Meis1 peaks with best reproducibility. The plot is peak-centered and ordered top to down according to Meis1 binding density. (B) Meis1 homes in on enhancer centers. Exemplary integrative genome viewer (IGV) panels demonstrating localization of Meis1 at the center of active enhancer modifications. (C) Meis1 marks typical hematopoietic enhancers. De novo motif search results of sequences +/-150 bp of Meis1 peaks yields putative binding sites for known hematopoietic transcription factors. (D) Distribution of identified binding motifs supports Meis1 or Meis1/HoxA9 composite binding at the center of identified chromatin immunoprecipitation peaks.
that either Meis or Meis/Hox composite consensus binding sites were present predominantly at the center of the majority of ChIP-enriched peaks (Figure 2C and D). These were accompanied by consensus sites for typical hematopoietic transcription factors like Cebp, Ets- and Runt-domain containing proteins. In summary, these results point to Meis1 as a transcription factor that localizes preferentially to active enhancers in myeloid precursor cells.

**HoxA9 is epistatic to Meis1**

In order to further elucidate the functional relationship between HoxA9, Meis1 and Pbx3 we recorded ChIP profiles for HoxA9 and Pbx3 in the newly generated Hox/Meis/Pbx lines and compared those to previously established HoxA9 binding patterns in the absence of Meis1 (Figure 3A and B). We and others have shown that Pbx3 forms physical heterodimers with Meis1 that are stable also in the absence of DNA. This was reflected in ChIP binding patterns with a nearly absolute congruency of Meis1 and Pbx3. Peaks correlated not only in location but also in binding density. As suggested by motif analysis, Meis1/Pbx3 peaks co-localized with areas of high HoxA9 occupancy and no “Meis-only” peaks were detected (Figure 3C, Online Supplementary Figure S2). Despite ChIP experiments being generated in parallel by exactly the same protocol in cell lines of identical etiology, HoxA9 binding was less sharp. We noticed this phenomenon before and this likely reflects the fact that HoxA9 has a more relaxed binding specificity, preferring AT-rich sequences. AT-rich stretches occur more frequently than the more defined Meis1 binding sites. Overall, HoxA9 binding was remarkably unaffected by the presence of Meis1. Binding profiles of HoxA9 from cells either in the absence or presence of Meis1 were superimposable and had a very good spearman correlation of 0.70 in global analysis (Figure 3B). This clearly suggested that HoxA9 binding is independent of Meis1, a molecular correlate to the fact that HoxA9 alone is able to immortalize hematopoietic cells.

In order to explore the reciprocal binding dependency we created a degradable HoxA9-FKBP36V fusion and used this construct to transform HSPC alone and in combination with Meis1. Western blots (Figure 3D, upper panel) confirmed the rapid destruction of HoxA9 in the resulting cell lines within 2 h after addition of the PROTAC while Meis1 levels were not affected. Phenotypically, degradation of HoxA9 did not cause cell death but led to a rapid differentiation of the precursor lines forming mature granulocytes and macrophages within 96 h (Figure 3D, lower panel). The presence of Meis1 did not alter this behavior indicating that Meis1 alone cannot maintain the undifferentiated, transformed state. At the molecular level the loss of HoxA9 was immediately followed by a loss of Meis1 from chromatin, with more than 90% of Meis1 disappearing in ChIP 2 h after initiating HoxA9 degradation (Figure 3E). This process did not alter Meis1 localization but rather affected the occupation density of all Meis1 peaks (Figure 3F). In summary, these results are best reconcilable with a role for Meis1 and Pbx3 to “sharpen” enhancer activity on chromatin pre-occupied by HoxA9.

**The Meis1-induced genetic program is dominated by Myc and ribosomal biogenesis.**

Next, we wanted to identify the genes under immediate control of Meis1 by nascent RNA sequencing. This procedure (Figure 4A) allows specific labeling, isolation, and sequencing of newly synthesized RNA through pulsed labeling of cells with 4-thiouridine reflecting thus RNA synthesis rates and transcription factor activity. Stable RNA, as determined by classical RNA sequencing, is subject to additional control mechanisms e.g., RNA export and degradation. In order to obtain a second independent experimental setup, we created an additional doxycycline-inducible (dox-inducible) Meis1 expression system (Figure 4B, upper panel). Because dox-based retroviral expression often suffers from variated expression, we used a fusion of a truncated LNGFR (low affinity nerve growth factor receptor) and Meis1 separated by a 2A “peptide bond breaker” (also called “self-cleavage” peptide) thus allowing for bicistronic expression. In this way, membrane-displayed LNGFR can be used to select and enrich properly expressing Meis1 cells. Western blots demonstrated the successful expression of Meis1 next to a minor amount of non-separated LNGFR-Meis1 fusion (Figure 4B, lower panel). EPC protease ko animals have no hematopoietic abnormality and there is no indication that the absence of cytoplasmic granule proteases affects HSPC specific genetic programs. Nevertheless, we set up the dox-inducible system in wt cells to call only those Meis1 target genes that are concordantly regulated in both genetic backgrounds. The doxycycline-inducible and degron constructs were tested for biological activity, checking their reversible ability to modulate transcription of the Meis1 sentinel gene Flt3 (Figure 4C). Both Meis1 derivatives induced Flt3 strongly, indicating their proper function. Guided by the Flt3 expression kinetics, nascent RNA was generated before and 24 h after degradation of Meis1-FKBP36V with dTAG13 at a time point when expression changes of this known primary target reached a maximum while keeping secondary effects to a minimum. Because of the considerable slower response of the dox system, reaction time was extended to 72 h for dox addition. Transcription rates in Meis1-on and Meis1-off states were determined in both systems by NG5 followed by mapping against the mm10 reference database. Genes with RPKM >1 were considered expressed and included in further analysis. We calculated the log2-fold changes between the Meis-on and Meis-off states for each gene in the dTAG-degradation and dox-inducible system and defined a gene as overall significantly changing if the sum of the respective log2-fold
ARTICLE - Meis1 as leukemogenic enhancer

M-P Garcia-Cuellar et al.

Continued on following page.
Figure 3. HoxA9 is epistatic to Meis1. (This figure is supplemented by the Online Supplementary Figure S2). (A) Meis1 and Pbx3 bind in a more defined pattern than HoxA9. Integrative genomics viewer (IGV) plots detailing binding of Meis1, Pbx3 and HoxA9 either in cells co-expressing Meis1 (HoxA9 + Meis1) or in cells in the absence of Meis1 (HoxA9_noMeis1). Sharp colocalized peaks for Meis1 and Pbx3 are different from more diffuse HoxA9 binding characteristics. (B) HoxA9 binding does not change after introduction of Meis1. Global comparison of HoxA9 binding in the vicinity of Meis1 peaks in cells transformed by HoxA9 or by HoxA9 in combination with Meis1 as indicated. (C) Meis1 and Pbx3 co-localize in areas of high HoxA9 density. Metagene plots depicting binding intensity of HoxA9, Meis1, and Pbx3 around identified Meis1 peaks. Heatmaps are ordered top to down according to decreasing Meis1 binding strength. Plotted are the 10,000 top-scoring Meis1 peaks as before. (D) Meis1 by itself cannot maintain the transformed state of precursor cells. Upper panel: western blot demonstrating rapid degradation of HoxA9-FKBP38 after addition of dTAG13 without affecting Meis1 protein levels. Lower panel: May–Grünwald–Giemsa stained cytospin preparations of hematopoietic stem and precursor cells (HPSC) lines generated after transduction either with HoxA9-FKBP38 alone or a combination of HoxA9-FKBP38 with Meis1. Cells are shown before and 96 hours (h) after induction of HoxA9 degradation by the addition of dTAG13. Differentiation with generation of mature granulocytic cells and macrophages is observed in both cases. (E) Meis1 rapidly leaves chromatin after HoxA9 degradation. IGV plots demonstrating Meis1 occupancy at Myb and Flt3 loci in the presence of HoxA9 and 2 h after induction of HoxA9 degradation. (F) Meis1 exits from chromatin rather than changes localization after loss of HoxA9. Global Meis1 read density comparison in the presence and after degradation of HoxA9. A global left shift of Meis1 densities combined with a relative maintenance of correlation indicates loss from chromatin rather than redistribution.

Changes was larger than one for induced genes or smaller than minus one for repressed genes \([\log_2(0\text{h}/24\text{h})_{\text{degron}} + \log_2(72\text{h}/0\text{h})_{\text{dox}} > 1 \text{or } < -1]\) (Online Supplementary Figure S3A). In total this yielded 492 induced genes (corresponding to 725 different GeneBank accession numbers) and 198 repressed genes (312 accession numbers) suggesting that Meis1 acts predominantly as activator. For visual representation in Figure 4D (Online Supplementary Figure S3A for repressed genes) RPKM values obtained in the individual experiments (dTAG-degradable, dox-inducible) were added. Because Meis1 recognizes pre-activated enhancers rather than creating de novo transcription, relative expression changes were mostly moderate. Of all Meis1-induced genes Myc was highest expressed. A Myc dominance was also corroborated by gene set enrichment analysis (GSEA). The Meis1-induced gene expression program showed an unusually good match with the Myc-expression profile deposited in the molecular signature database (MSigDB) (Figure 4D, inset and Online Supplementary Figure S3B). This fit well with strong Meis1/Pbx3 binding occurring at the known long-range Myc enhancer (Online Supplementary Figure S3C). A further conspicuous feature of Meis1 controlled expression was the upregulation of a large number of genes coding for ribosomal and ribosomal biogenesis components. This included ribonucleoproteins, ribosome biogenesis regulator 1, nucleolar proteins, small nucleolar RNA and/or their respective host genes and also subunit D of RNA polymerase I (Polr1d), the sum of which we label “ribosomal cloud”. This feature was also corroborated by GSEA (Online Supplementary Figure S3D). Regulation of ribosomal genes by Meis1 was supported by direct Meis1 binding in the vicinity of the respective genes as exemplary shown for the top ten genes that characterize the molecular signature “KEGG_ribosome” in GSEA (Online Supplementary Figure S4A and B). In primary acute myeloid leukemia (AML) samples generated from 562 patients, Pearson correlation between MEIS1 and these ribosomal genes generally amounted to between 0.2 and 0.3 (Online Supplementary Figure S4C). In order to put this in perspective, the well established Meis1 target FLT3, with a much larger regulatory amplitude (several orders of magnitude) compared to ribosomal genes, reached a correlation of 0.42 in this data set. Therefore we conclude that Meis1 is likely also involved in ribosomal transcription in human AML. Reflecting the precursor nature of HSPC transformed by HoxA9/Meis1, genes repressed by Meis1 encompassed differentiation promoting factors like Npg (neutrophil granule protein), Cebpe (CAAT enhancer binding protein epsilon) and Id2 (inhibitor of DNA binding 2). In line with a physically largely overlapping binding pattern of HoxA9 and Meis1 about 40% (175/461) of all Meis1 targets, including Myc, have been also found to be positively controlled by HoxA9 in our previous study\(^21\) (Figure 4D, inset). This overlap was even greater for Meis1 repressed transcripts with 111/198 genes also showing a similar response to HoxA9 (Online Supplementary Figure S3A, inset). This supports a role of Meis1 as amplifier of a transformative state pre-established by HoxA9.

**Myc recapitulates the proliferative aspect of Meis1 expression**

In order to elucidate individual contribution of downstream targets to the overall Meis1 phenotype we decided to further investigate the known oncogenes Myc, and JunB as the two most strongly expressed Meis1 targets and the regulatory outlier Angptl4 that codes for a soluble growth factor involved in the etiology of various solid tumors.\(^34\) After confirming their Meis1-dependent transcription (Figure 5A), these genes were individually transduced into HoxA9 pre-transformed primary HSPC. Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) confirmed that their expression exceeded the levels observed in HoxA9/Meis1 cells (Figure 5B). In addition, we verified that these targets do not feed back and induce Meis1 expression themselves (Online Supplementary Figure S5). We recorded proliferation, cell cycle...
Meis1 as leukemogenic enhancer

M-P Garcia-Cuellar et al.

A

HoxA9 +

Meis1

Fkbp

primary precursors

transduction

add dTAG13

or doxycycline
treatment

4-thiouridine

purification

RNAseq

kinetics

Haematologica | 107 November 2022

2608

ARTICLE

-rnAseq

Meis1

HoxA9

Meis1

or doxycycline

nascent RNA-seq

NGS

B

LTR(SIN)

Meis1

pTA3

RES puro

LTR(SIN)

dox-1 Prom

Meis1

-0h

72h

kDa

WB:HA

C

qPCR (Flt3)

+dox

-dox

+dTAG13

-dTAG

+dTAG13

0

50

100

150

h

rigosomal "cloud"

Angptl4

Meis induced

top_exp

top30 outlier

D

100

10

1

sum RPKM Meis on (0h dTAG + 72h dox)

sum RPKM Meis off (24h dTAG + 0h dox)

FDR = 0.0

P = 0.0

NES = 2.05

Continued on following page.
Figure 4. The Meis1 induced gene expression program is dominated by Myc and ribosome biogenesis. (This figure is supplemented by the Online Supplementary Figure S3 and S4 and the Online Supplementary Table S1). (A) The primary Meis1 controlled gene expression program can be determined by nascent RNA sequencing. Overview of experimental strategy. (B) Meis1 expression can be positively induced in a doxycycline (dox)-controlled system. Schematic depiction of an “all-in-one” inducible expression system based on a self-inactivating (SIN) retroviral backbone. LTR: long terminal repeat, self-inactivating after proviral integration; LNGFR: truncated low affinity growth factor receptor displayed on membrane for antibody-based (anti human CD271) cell selection; 2A: viral-derived “self-cleaving” peptide, blocking peptide bond formation during translation and thus allowing expression of two proteins from fusion sequence; rTA3: reverse tetra/dox-inducible transactivator of 3rd generation; IRES: internal ribosomal entry site, puro: puromycin resistance. The western blot shows expression of HA-Meis before and 72 hours (h) after addition of dox in transduced hematopoietic stem and precursor cells (HPSC). Small amounts of full length LNGFR-2A-Meis1 fusion are also visible. The western was done with hot SDS extracts as the dox-inducible Meis1 system was introduced in wild-type (wt) cells. (C) The conditional Meis1 expression constructs are biologically active. The amount of RNA coding for the Meis1 sentinel gene Flt3 was determined by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) in a time series either after induction of Meis1 expression by dox addition or after induction of Meis1-FKBPF36 degradation by supplementation with dTAG13. In order to demonstrate reversibility inducers were washed out after 48 h and re-added again after 120 h. Values were normalized to actin transcripts and starting amounts before treatment were defined as one unit. (D) Meis1 induces a Myc and ribosome-synthesis dominated gene expression program. Transcription rates in inducible Meis1 cells were determined in the Meis_on (72 h dox-added or dTAG13 absent) and in the Meis_off state (dox-absent or 24 h DTAG13 present) by nascent RNA sequencing. For graphical representation RPMK expression values for each gene bank accession number were added and plotted in Meis_on and Meis_off states. Shown are values (collapsed to individual genes) for all genes with a significant induction defined as log2(RPKMmeis_on/RPKMmeis_off) > 0.5 vs dox + log2(RPKMmeis_on/RPKMmeis_off) > 1.0. Red dots denote the top 30 outliers in gene expression change. The top 100 expressed accessions are colored orange (aggregated to gene names). Red labels identify genes investigated further. The left inset shows a Venn-diagram displaying overlap of primary Meis1-induced transcripts with HoxA9 targets identified previously21 by a similar approach. The right inset depicts the top-scoring result of a gene set enrichment analysis demonstrating a strong similarity of the Meis1-induced expression pattern to the known Myc-regulated program.

distribution and colony forming cell (CFC) numbers of doubly transduced cells. In these experiments Myc fully mimicked the cell cycle and proliferation stimulation by Meis1 (Figure 5C and D) but neither JunB nor Angptl4 recorded any effect. High Myc levels also increased CFC numbers, but due to the replicative variability in replating assays, the moderate effect of the other genes remained insignificant (Figure 5E).

Transformed cells derived from primary HSPC need high levels of cytokines (SCF, IL-3, GM-CSF, and IL6) for viability and growth. Recording cytokine dependency in MTT viability/growth tests allows judging if Meis1 or any of its target genes influence cellular signaling. In these experiments only Myc showed a tendency to alleviate dependency on cytokines (Figure 6A). All others including Angptl4 coding for a known signaling molecule were inactive, thus largely ruling out an impact on signal processing as crucial for enhanced leukemogenesis.

Next, we probed the influence of Meis1 and the selected target genes on cellular differentiation. HoxA9 transformed cells can be forced to differentiate in vitro by replacing the growth cytokine mixture by G-CSF. Morphologically Meis1 and Myc expression retarded differentiation (Figure 6B, upper panel) with no effect recorded for JunB and Angptl4 (not shown). The concomitant downregulation of surface Kit (CD117) was slower for Meis1 co-expressing cells (Figure 6B, lower panel) with CD117 still detectable after 72 h of G-CSF treatment.

Finally, we tested if Myc accelerates leukemogenesis similar to Meis1 in syngenic transplantation experiments (Figure 6C). Whereas HoxA9/Meis1-transduced cells caused rapid and fully penetrant disease in the recipient animals this was clearly not the case for HoxA9/Myc cells. This result was additionally supported by a recent report of Miyamoto et al.20 that performed comparable experiments with longer follow-up. Thus two independent studies confirmed that Myc does not fully substitute for Meis1 in leukemogenesis despite the fact that Myc can explain the proliferative aspect of Meis1 expression. Therefore, Meis1 clearly has functions beyond a simple Myc enhancer.

Meis1 boosts ribosomal biogenesis

The salient abundance of ribosomal biogenesis components under Meis1 control led us to check if Meis1 also influences rRNA transcription. For this purpose we quantified 18s rRNA by RT-qPCR in the Meis–FKBP36 system during a cycle of addition/withdrawal/addition of dTAG13 (Figure 7A). As ribosomal loci are not annotated in the mouse genome (version mm10) it is difficult to calculate rRNA transcriptional rates from the sequencing data. Yet, qPCR confirmed that 18s rRNA concentrations clearly followed Meis1 activity. The Meis1-dependent stimulation of rRNA transcription translated to a significantly higher resistance of Meis1-containing cells against CX5461, an inhibitor of RNA polymerase I (Figure 7B). Importantly, this was not observed with Myc-overexpressing cells thus underscoring this fact as unique property of Meis1.

The presence of Meis1 also conferred higher resilience to puromycin treatment in MTT viability assays (Figure 7C). Puromycin is a translation chain terminator that incapacitates actively transcribing ribosomes. Cells that are able to replace stalled ribosomes at a faster pace are expected to be more puromycin resistant. This was clearly observed for Meis1 but much less pronounced after sole
expression of Myc. Notably, Meis1 did not simply induce a
general tolerance against toxins because treatment of
cells with the DNA-intercalating agent doxorubicine did
not reveal a differential sensitivity of the respective cells
(Figure 7D).

We also checked the concentration of ribosomal protein
S6, its phosphorylation status, as well as overall protein
synthesis rates by short-term incorporation of a fluo-
rescently labeled puromycin derivative (OPP-puro assay).
These assays did not indicate a significantly elevated
number of ribosomes or an increase in overall protein syn-
thesis capacity. A slight increase of S6 induced by Meis1
and Myc was counteracted by a concomitant reduction in
phospho-S6 (Figure 7E). As a consequence the overall pro-
tein synthesis activity was unchanged between the indi-
vidual cell lines (Figure 7F). This indicates that Meis1
enhances the synthesis rate of ribosomes rather than their
final activity under steady state conditions.

HoxA9 and Meis1 stability are regulated by
phosphorylation

During the normal trajectory of hematopoietic devel-
opment, cells must exit the highly proliferative precursor
state and therefore they need to curb the pro-proliferative
activity of HoxA9 and Meis1 at some point. Previously, we
have shown that Meis1 stability is regulated by Pbx3. Pbx3
interacts with Meis1 blocking access to an ubiquitination
site and as a consequence it inhibits proteasomal degra-
dation.4 This mechanism has a slow response rate, as it
requires the cessation of Pbx3 transcription and the loss of
remaining Pbx3 protein. In an attempt to identify faster act-
acting regulatory mechanisms, we scanned the PhosphoSite-
Plus database (www.phosphosite.org) for known
post-translational modifications of Meis1. Strong phos-
phorylation of Meis1 has been detected at a serine stretch
between amino acids (aa) 192 and aa 200 with the highest
modification density occurring on S196 (Figure 8A). Because

Figure 5. Myc controls the proliferative aspect of Meis1 activity
(This figure is supplemented by the Online Supplemental Figure
S5). (A) Myc, JunB, and Angptl4 are direct targets of Meis1. Transcription rates of Myc, JunB, and Angptl4 were determined by
reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) on nascent RNA isolated in a time series after
induction/degradation of Meis1. The response kinetics suggest direct control by Meis1. (B) Individual expression of single target
genes. RT-qPCR after transduction of HoxA9-transformed cells with individual Meis1 target genes demonstrates higher
expression than in HoxA9 + Meis1 cells. (C) Myc and Meis1 accelerate cell proliferation. Individual cell lines, transduced as labeled
were cultivated under identical conditions and cell proliferation was determined by counting triplicates. *P<0.05 in two-sided t-
test. (D) Myc and Meis1 induce cell cycle. Propidium-iodide staining of test cell lines demonstrates more cells in cell cycle (S/M
and G2 phases) as consequence of Meis1 or Myc coexpression. Values correspond to averages and standard deviations of
triplicate experiments. **P<0.05 in two-sided t-test. (E) Myc increases colony forming cell (CFC) numbers. CFC capacity was
tested for all test lines by seeding 5,000 cells in triplicate into semi solid methylcellulose medium and by counting resulting
colonies after 4 to 6 days of incubation. Average and standard deviation is given. *P<0.05 in two-sided t-test.
this is immediately downstream of the Pbx3 interaction site, we decided to study the influence of phosphorylation on Meis1 stability and Pbx3 binding. For this purpose, we constructed a phosphomutant version replacing three serines against alanine (Meis_AKADA) and a phosphomimetic version (Meis_DKDD) introducing two negatively charged aspartic acid (D) residues. The effect of the mutations on stability was tested first by transfection of wt Meis1 and the respective phospho-mutants together with Pbx3 into 293T cells. A Meis1 deletion eliminating Pbx3 binding served as additional control (Figure 8B). Phosphorylation/site mutants and Pbx3 co-expression had independent effects on Meis1 stability. Co-expression of Pbx3 increased detectable Meis1 protein for each mutant derivative and this effect was inverted upon deletion of the Pbx3 interaction domain an effect that we have observed earlier. However, phospho-site mutations had a clear Pbx3-independent effects on Meis1 stability. The phosphomimetic Meis-DKDD accumulated to much higher levels than wt-Meis1 whereas the phospho-defective Meis-AKADA showed reduced stability. A similar reduction of phospho-defective Meis1 amounts was also seen after transduction of HSPC with HoxA9 and the re-
Figure 7. **Meis1 boosts ribosomal biogenesis capacity.** (A) Ribosomal RNA (rRNA) transcription correlates with Meis1 activity. Total RNA was isolated from cells transformed by HoxA9 and Meis1-FKBP36V in a time series after induction of Meis1, degradation, recovery, and a second degradation phase. Concentrations of 18S rRNA were determined by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) and are plotted relative to the starting value. (B) Meis1 increases resistance against RNA polymerase I inhibition. Cells transduced as indicated were subjected to treatment with increasing concentrations of the RNA polymerase I inhibitor CX5461 and viability was determined by MTT assay. Values are plotted based on untreated cells set to one unit. Averages and standard deviation of a triplicate are shown. (C) Meis1 cells increases resilience towards puromycin. Experiment done as above. (D) Co-expression of Meis1 or Myc does not alter sensitivity towards doxorubicine. (E) Meis1 and Myc have a minor influence on steady state and phosphorylation levels of ribosomal protein S6. Cells transduced as indicated were lysed, and the equivalent of 40,000 cells were loaded per lane on a SDS PAGE for detection with S6 and phospho-S6 specific antibodies. (F) Meis1 and Myc do not alter steady-state protein synthesis rate. Cells were incubated with O-propargyl-puromycin (OPP) for 30 minutes, fixed and then OPP was conjugated with Alexa-Fluor 488 and chain-terminated translation products were recorded by fluorescence-activated cell sorting.
Figure 8. Meis1 and HoxA9 stability is controlled by caseine kinase 2-mediated phosphorylation. (A) Meis1 contains a phosphorylation site closely downstream of the Pbx3 binding domain. Schematic depiction. (B) Pbx3 and phosphorylation control Meis1 stability independently. Wild-type Meis1 (Wt-Meis1), a phosphodefective mutant (AKADA) exchanging respective serines against alanines, as well as a phosphomimetic version (DKDD) mimicking modification by introduction of negative charges were transfected with and without Pbx3 in 293T cells. Meis1 stability was recorded by western blot. Meis1 with a deletion of the Pbx3 binding domain was added as additional control. (C) Meis1_AKADA is unstable in primary myeloid cells. Hematopoietic stem and precursor cells (HPSC) were transduced as indicated and the resulting cell lines were tested for Meis1 and HoxA9 expression by western blot. (D) Inhibition of caseine kinase 2 reduces Meis1 and HoxA9 concentrations and phosphomimetic mutants are resistant. Primary cells transduced with wt HoxA9 and either wt-Meis1 or Meis1_DKDD were treated for 4 hours (h) with increasing concentrations of the caseine kinase 2 inhibitor CX4945 as indicated. Cell extracts were probed by western blotting for Meis1 and HoxA9. (E) HoxA9 is regulated by casein kinase 2. Upper panel: schematic location of the known HoxA9 phosphorylation site. Lower panel: western blots made with extracts from cells transduced with phosphomimetic versions of HoxA9 (HoxA9_DGGD) and Meis1 (Meis1_DKDD) probed for HoxA9 and Meis1 after treatment with CX4945. (F) Left panel: densitometric evaluation of protein stability under casein kinase 2 inhibition. Protein amounts of HoxA9 and Meis1 wt and phosphomimetic versions were determined by densitometric analysis and normalization to actin levels corresponding to western blots shown in (D), left and (E). Right panel: introduction of phosphomimetic HoxA9 and Meis1 mutants does not significantly increase overall resistance of cells against casein kinase 2 inhibition. Cells transduced either with wt versions or with phosphomimetic variants of HoxA9 and Meis1 as indicated were subject to varying concentrations of the caseine kinase inhibitor CX4945 for 72 h and viability/proliferation was tested by MTT assay. Relative values are plotted with untreated cells set to one unit.
spective Meis1 derivatives (Figure 8C). In contrast to the transient system where the large amounts of protein likely cannot be fully modified, in primary cells wt-Meis1 was as stable as phosphomimetic Meis-DKDD suggesting that Meis1 is fully phosphorylated in these cells.

Next, we determined the responsible kinase for this modification. As the respective serines are embedded in a casein kinase 2 (CK2) consensus site, we treated wt-Meis1 and phosphomimetic Meis-DKDD-transduced HSPC with increasing concentrations of a specific CK2 inhibitor (CX4945) and determined short term effects on HoxA9 and Meis1 concentrations after 4 h by western blot (Figure 8D). In these experiments CK2 activity correlated closely with Meis1 concentrations (Figure 8D, left panel) and introduction of the phosphomimetic changes conferred resistance to CK2 inhibition (Figure 8D, right panel). Unexpectedly, we noted that also HoxA9 responded to a block of CK2 function. According to the PhosphoSite database HoxA9 is phosphorylated at serine 183 that is located within another CK2 consensus site (Figure 8E, upper panel). Alteration of this serine to aspartic acid to create a phosphomimetic HoxA9-DGGD and introduction of this mutant together with Meis1-DKDD into HSPC yielded cells where both, HoxA9 and Meis1 were resistant to CK2 inhibition (Figure 8E, lower panel and see Figure 8F, left panel for a summarized densitometric evaluation). Therefore we conclude that CK2 is an important natural regulator of Hox/Meis activity in primary cells. With respect to application in patients, the current general CK2 inhibitors are suboptimal. It has been estimated that CK2 phosphorylates up to 20% of all proteins in a cell. Therefore, CK2 inhibitors may have a small therapeutic window. This was reflected by the fact that cells transformed with either wt-HoxA9/wt-Meis1 or with a combination of their phosphomimetic counterparts showed a nearly identical response towards CK2 inhibition by CX4945 (Figure 8F, right panel) indicating that other, unknown CK2 targets also limit overall viability in these cells.

Discussion

Here we provide the molecular correlate of the experimental observation that Meis1 enhances leukemogenesis in combination with HoxA9 while on its own it has no discernible effect on hematopoietic development. Despite the fact that Meis1 and its binding partner Pbx3 contain autonomous homeobox DNA binding domains, HoxA9 is epistatic in hematopoietic cells. In the absence of HoxA9, Meis1 cannot maintain a stable DNA interaction and exits from chromatin. While an increased avidity for DNA of HoxA9/Meis1 dimers and HoxA9/Meis1/Pbx3 trimers was suggested previously by in vitro co-precipitation experiments the rapid loss of Meis1 at its binding sites in vivo was unexpected. Previous experiments insinuated that dimerization of transcription factors would modify binding site specificity i.e., directing dimers to different binding sites compared to monomers. Instead, the presence of Meis1 endows enhancers pre-bound by HoxA9 with additional activity without altering HoxA9 distribution itself. This makes HoxA9 a bona fide pioneering transcription factor, a fact that is strongly supported by the finding that HoxA9 can induce de novo enhancers. HoxA9 by itself appears to have a more relaxed in vivo DNA binding specificity, characterized by a “diffuse” distribution. In combination with Meis1, chromatin areas are demarcated that define the center of functional enhancers. Meis1 peaks delineate the “valleys” of regions with high levels of enhancer modifications H3K27ac and H3K4me1. Thus, Meis1 focuses and concentrates enhancer activity, an effect that we call “enhancer sharpening”. It is easy to see how this process may aid to develop an increasingly active and novel enhancer architecture from previously inactive chromatin during differentiation of HSC into highly proliferative precursors.

The effect of enhancer sharpening rather than the creation of completely new transcriptional elements fits well to the gene expression changes that we observed after induction of Meis1. Mainly, Meis1 intensified a pre-existing and primarily HoxA9-dependent gene expression pattern. Still, amplification of Myc action and the strong stimulation of ribosome biogenesis are crucial and contribute to the phenotypic manifestation of Meis1 expression. Myc, as a predominantly proliferative driver has been shown to be a major factor in the HoxA9-dependent gene expression program. Cell division, however, is strongly regulated at several levels, and besides cell cycle stimulation, it requires previous cell growth i.e., an increase in cellular mass. As ribosomal proteins constitute the most abundant proteins in a cell and rRNA is responsible for >90% of all RNA, synthesis of new ribosomes as preparation for actual cell division is a major bottleneck. Details about ribosome biogenesis checkpoint regulation are not yet completely clarified but it is clear that cell division cannot be executed without sufficient ribosomes. As a consequence cells with high expression of cell cycle drivers, like Myc become addicted to high ribosomal biogenesis rates, a fact that has been recently also shown for Myc induced lymphoma. The extraordinary sensitivity of hematopoietic development towards perturbation in ribosome biogenesis is underscored by the hematopoietic phenotype of ribosomopathies. Meis1 expression helps to satisfy ribosomal biosynthesis requirements of normal hematopoietic precursors and obviously also as prerequisite for efficient leukemogenesis. Strikingly, an essential step during ribosome maturation, the snRNa guided modification of rRNA, has been recently shown to be a crucial hallmark also of the AML-ETO-induced leukemogenic gene expression program.
It is still difficult to target transcription factor activity for therapeutic purposes. Elucidating how normal cells regulate transcriptional activity may reveal possible solutions to this problem. We show that posttranscriptional phosphorylation of HoxA9 and Meis1 by casein kinase 2 is one mechanism how cells regulate activity of these two factors. This process is highly conserved during evolution as there is evidence that the insect homolog of caseine kinase 2 controls activity of the fly homebox protein antennapedia during embryogenesis. Casein kinase 2 is constitutively active, yet that pertains to cells in culture that are permanently cycling. It is not completely clear if this is also true for mostly non-cycling primary cells. CK2 inhibitors are tested in early clinical trials for various advanced solid and hematopoietic tumors. Results have not been published yet and it will be seen if an exploitable therapeutic window exists. The mechanism how cells regulate activity of these two factors is highly conserved during evolution as there is evidence that the insect homolog of caseine kinase 2 controls activity of the fly homebox protein antennapedia during embryogenesis. Casein kinase 2 is constitutively active, yet that pertains to cells in culture that are permanently cycling. It is not completely clear if this is also true for mostly non-cycling primary cells. CK2 inhibitors are tested in early clinical trials for various advanced solid and hematopoietic tumors. Results have not been published yet and it will be seen if an exploitable therapeutic window exists. The finding that CK2 acts extremely pleiotropic is a caveat, but the rapid and direct response of HoxA9 and Meis1 to a small molecule treatment of an orally available inhibitor at least hints to a promising starting point for further drug development.

Disclosures
No conflicts of interest to disclose.

Contributions
MPGC, and RKS performed and analyzed experiments; AP cloned and tested degron constructs; RKS performed NGS data analysis, conceived and supervised experiments; RKS wrote the manuscript. All authors read and discussed the manuscript.

Acknowledgements
We thank Renate Zimmermann for technical assistance.

Funding
This work was supported by research funding from Deutsche Krebshilfe grant 70114166 and in part by the Deutsche Forschungsgemeinschaft grant SL27/9-2 both awarded to RKS.

Data-sharing statement
NGS reads are available with the European Nucleotide Archive under accession number ERP134562/PRJEB50012.

References
1. Collins CT, Hess JL. Deregulation of the HOXA9/MEIS1 axis in acute leukemia. Curr Opin Hematol. 2016;23(4):354–361.
2. Collins EM, Thompson A. HOX genes in normal, engineered and malignant hematopoiesis. Int J Dev Biol. 2018;62(11–12):847–856.
3. Berthelsen J, Kilstrup-Nielsen C, Blasi F, Mavilio F, Zappavigna V. The subcellular localization of PBX1 and EXO proteins depends on nuclear import and export signals and is modulated by association with PREP1 and HTH. Genes Dev. 1999;13(8):946–953.
4. Garcia-Cuellar MP, Steger J, Fuller E, Hetzner K, Slany RK. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia. Haematologica. 2015;100(7):905–913.
5. Dickson GJ, Liberante FG, Kettle LM, et al. HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. Haematologica. 2013;98(8):1216–1225.
6. Li Z, Chen P, Su R, et al. PBX3 and MEIS1 Cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-rearranged disease. Cancer Res. 2016;76(3):619–629.
7. Li Z, Zhang Z, Li Y, et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood. 2013;121(8):1422–1431.
8. Thorsteinsdottir U, Kroon E, Jerome L, et al. PBX3 and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21(1):224–234.
9. Wang GG, Pasillas MP, Kamps MP. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. Blood. 2005;106(1):254–264.
10. Ambinder AJ, Levis M. Potential targeting of FLT3 acute myeloid leukemia. Haematologica. 2021;106(3):671–681.
11. Morgado E, Albouhair S, Lavau C. Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation. Blood. 2007;109(9):4020–4022.
12. Staffas A, Arabanian LS, Wei SY, et al. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice. Oncogene. 2017;36(11):1516–1524.
13. Mohr S, Doebele C, Comoglio F, et al. Hoxa9 and Meis1 cooperatively induce addiction to Syk signaling by suppressing miR-146a in acute myeloid leukemia. Cancer Cell. 2017;31(4):549–562.e11.
14. Kocabas F, Zheng J, Thet S, et al. Meis1 regulates the metabolic phenotype and oxidant defense of hematopoietic stem cells. Blood. 2012;120(25):4963–4972.
15. Simsek T, Kocabas F, Zheng J, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010,7(3):380–390.
16. Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8(4):399–411.
17. Yusuf RZ, Wang YH, Scadden DT. The secrets of the bone marrow niche: Metabolic priming for AML. Nat Med. 2012;18(6):865–867.
18. Sullima SO, Hofman IJF, De Keersmaecker K, Dinman JD. How ribosomes translate cancer. Cancer Discov. 2017;7(10):1069–1087.
19. Chlon TM, Stepanchick E, Hershberger CE, et al. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021;28(11):1966–1981.e6.
20. Miyamoto R, Kanai A, Okuda H, et al. HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene expression for multiple anti-apoptotic pathways. Elife. 2021;10:e64148.
21. Zhong X, Prinz A, Steger J, et al. HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes. Blood Adv. 2018;2(22):3137–3148.
22. Guyot N, Wartelle J, Malleret L, et al. Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage.
and emphysema. Am J Pathol. 2014;184(8):2197-2210.
23. Milne TA, Zhao K, Hess JL. Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. Methods Mol Biol. 2009;538:409-423.
24. Garcia-Cuellar MP, Buttner C, Bartenhagen C, Dugas M, Slany RK. Leukemogenic MLL-ENL fusions induce alternative chromatin states to drive a functionally dichotomous group of target genes. Cell Rep. 2016;15(2):310-322.
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760.
26. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
27. Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576-589.
28. Ramirez F, Ryan DP, Gruning B, et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44(W1):W160-165.
29. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
30. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079.
31. Wu T, Yoon H, Xiong Y, Dixon-Clarke SE, Nowak RP, Fischer ES. Targeted protein degradation as a powerful research tool in basic biology and drug target discovery. Nat Struct Mol Biol. 2020;27(7):605-614.
32. Bahr C, von Paleske L, Uslu VV, et al. A Myc enhancer cluster regulates normal and leukemic haematopoietic stem cell hierarchies. Nature. 2018;553(7689):515-520.
33. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526-531.
34. Fernandez-Hernando C, Suarez Y. ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis. Curr Opin Hematol. 2020;27(3):206-213.
35. Spinello Z, Fregnani A, Quotti Tubi L, Trentin L, Piazza F, Manni S. Targeting protein kinases in blood cancer: focusing on CK1alpha and CK2. Int J Mol Sci. 2021;22(7):3716.
36. Ryoo HD, Marty T, Casares F, Affolter M, Mann RS. Regulation of Hox target genes by a DNA bound Homothorax/Hox/Extradenticle complex. Development. 1999;126(22):5137-5148.
37. Jolma A, Yin Y, Nitta KR, et al. DNA-dependent formation of transcription factor pairs alters their binding specificity. Nature. 2015;527(7578):384-388.
38. Sun Y, Zhou B, Mao F, et al. HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer Cell. 2018;34(4):643-658.e5.
39. Lessard F, Brakier-Gingras L, Ferbeyre G. Ribosomal proteins control tumor suppressor pathways in response to nucleolar stress. Bioessays. 2019;41(3):e1800183.
40. Domostegui A, Peddigari S, Mercer CA, et al. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. Blood. 2021;137(24):3351-3364.
41. Zhou F, Liu Y, Rohde C, et al. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nat Cell Biol. 2017;19(7):844-855.
42. Jaffe L, Ryoo HD, Mann RS. A role for phosphorylation by casein kinase II in modulating Antennapedia activity in Drosophila. Genes Dev. 1997;11(10):1327-1340.